- Stanley, Christopher, Maghzal, Ghassan, Ayer, Anita, Talib, Jihan, Giltrap, Andrew, Shengule, Sudhir, Wolhuter, Kathryn, Wang, Yutang, Chadha, Preet, Suarna, Cacang, Prysyazhna, Oleksandra, Scotcher, Jenna, Dunn, Louise, Prado, Fernanda, Nguyen, Nghi, Odiba, Jephthah, Baell, Johathan, Stasch, Johannes-Peter, Yamamoto, Yorihiro, Di Mascio, Paolo, Eaton, Philip, Payne, Richard, Stocker, Roland
Comment : Translating guidelines into practice : Interpreting the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL cholesterol lowering in the management of atherosclerotic cardiovascular disease risk
Ambulatory blood pressure may be designed as the primary efficacy outcome in clinical trials on renal denervation
Could pathophysiology failure be ruled out?
It is urgent to investigate predictors of the response of blood pressure to renal denervation
It may be not suitable to perform renal denervation in renal arteries with significant stenosis
Letter by Wang Regarding Article, “Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?”
Limitations in current clinical trials on renal denervation
Single-sided renal denervation may be not suitable for patients with significant renal artery stenosis
What is the true incidence of renal artery stenosis after sympathetic denervation?
Are you sure you would like to clear your session, including search history and login status?